Before getting into the detail, the key question is simple: at around US$438.34 per share, is Thermo Fisher Scientific stock offering good value for the risks you are taking on?

Over the last week the share price declined 5.7%, over the last month it fell 17.6%, and year to date the stock is down 26.0%, although the 1 year return sits at 6.8%, which may catch the eye of investors watching for changing sentiment.

Recent coverage has focused on Thermo Fisher Scientific in the context of ongoing interest in life sciences tools, acquisitions in the sector, and the role of large, diversified players when investors reassess risk in healthcare related stocks. That backdrop helps explain why the share price can move sharply over short periods even when the long term story appears more stable.

On Simply Wall St's valuation checks, Thermo Fisher Scientific currently scores 6 out of 6 for being assessed as undervalued across different measures. The sections that follow will break down those methods, then finish with a framework that can help you think about valuation in a more complete way than any single model on its own.

Approach 1: Thermo Fisher Scientific Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model projects a company’s future cash flows and then discounts them back to today’s dollars to estimate what the business might be worth right now.

For Thermo Fisher Scientific, Simply Wall St uses a 2 Stage Free Cash Flow to Equity model. The latest twelve month Free Cash Flow is about $6.79b. Analyst and extrapolated projections suggest Free Cash Flow reaching about $11.45b by 2030, with a path of forecast and extrapolated values between 2026 and 2035 feeding into the model.

Those projected cash flows are discounted back to today using a required rate of return, producing an estimated intrinsic value of about $605.29 per share. Compared with the recent share price of around $438.34, the model output indicates an implied discount of roughly 27.6% on this DCF view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Thermo Fisher Scientific is undervalued by 27.6%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks.

Approach 2: Thermo Fisher Scientific Price vs Earnings

For profitable companies, the P/E ratio is a straightforward way to connect what you pay for the stock with the earnings it currently generates. This is often how investors quickly compare opportunities.

What counts as a "normal" or "fair" P/E depends on how fast earnings are expected to grow and how risky those earnings are. Higher growth and lower perceived risk typically justify a higher P/E, while slower growth or higher risk usually point to a lower one.

Thermo Fisher Scientific currently trades on a P/E of about 23.79x. This sits below the Life Sciences industry average P/E of about 34.39x and also below the broader peer group average of about 36.98x. Simply Wall St’s Fair Ratio for Thermo Fisher Scientific is 26.14x. This Fair Ratio is a proprietary estimate of what the P/E might be given factors such as earnings growth, industry, profit margins, market cap and risk profile.

Because the Fair Ratio incorporates these company specific drivers, it can be more informative than a simple comparison with peers or the industry alone. With the current P/E of 23.79x sitting below the Fair Ratio of 26.14x, the stock appears undervalued on this P/E based view.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Thermo Fisher Scientific Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach a clear story to your numbers by linking a view on Thermo Fisher Scientific's future revenue, earnings, margins and fair value to a shared forecast that sits in the Community page. The narrative then compares that fair value to the current price to help you consider whether the stock fits your criteria, while automatically updating as new news or earnings arrive.

For example, one Thermo Fisher Scientific Narrative on the Community page might look closer to the high end, using a fair value around US$738.42 with revenue growth assumptions near 7.8%, profit margins near 17.7% and a future P/E of about 33.6x. Another might sit nearer the low end, using a fair value around US$520.00 with revenue growth assumptions near 5.8%, profit margins near 15.7% and a future P/E of about 28.1x. Both can coexist so you can see in one place how different investors interpret the same stock through different stories and numbers.

Do you think there's more to the story for Thermo Fisher Scientific? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.